| Bioactivity | Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity[1]. |
| Invitro | Tecaginlimab 结合重组人 CD40 和 4-1BB，亲和力分别为 1.0 nM 和 0.17 nM[1]。Tecaginlimab (0.001-1 µg/mL; 5 d) 在体外诱导树突状细胞 (DC) 成熟[1]。Tecaginlimab (0.2 µg/mL; 10-15 d) 在体外增强 T 细胞活化[1]。 |
| In Vivo | Tecaginlimab (0.0008-0.2 µg/mL; 4 d) 增强肿瘤浸润淋巴细胞的扩增[1]。 |
| Name | Tecaginlimab |
| CAS | 2253891-70-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Muik A, et, al. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity. J Immunother Cancer. 2022 Jun;10(6):e004322. |